1.27
전일 마감가:
$1.40
열려 있는:
$1.37
하루 거래량:
143.61K
Relative Volume:
0.92
시가총액:
$1.27M
수익:
-
순이익/손실:
$-9.29M
주가수익비율:
-0.2442
EPS:
-5.2
순현금흐름:
$-9.42M
1주 성능:
-13.10%
1개월 성능:
-4.51%
6개월 성능:
-54.32%
1년 성능:
-64.33%
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
명칭
Scinai Immunotherapeutics Ltd Adr
전화
972-8-9302529
주소
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
SCNI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
1.27 | 4.46M | 0 | -9.29M | -9.42M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Scinai Immunotherapeutics Ltd Adr 주식(SCNI)의 최신 뉴스
Scinai receives $246,000 grant to expand biotech manufacturing By Investing.com - Investing.com South Africa
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports First-Half 2025 Results, Strengthened Cash Position - Barchart.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Barchart.com
Scinai Immunotherapeutics (NASDAQ:SCNI) Trading Down 3.8% – Here’s What Happened - Defense World
Scinai Immunotherapeutics Ltd ADR (SCNI) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Publishes Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier - Barchart.com
Scinai Immunotherapeutics stock soars on promising skin disease drug data By Investing.com - Investing.com South Africa
Scinai Immunotherapeutics stock soars on promising skin disease drug data - Investing.com Australia
Scinai’s PC111 antibody shows promise for pemphigus treatment By Investing.com - Investing.com Canada
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com India
ICICI Bank Ltd. ADR (IBN) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - Benzinga
Augusta Gold (TSE:G) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
Scinai Immunotherapeutics Faces Financial Challenges, Seeks Growth - TipRanks
Scinai Immunotherapeutics Reports Strong CDMO Growth - TipRanks
Scinai Immunotherapeutics (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary - Barchart.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports $4.8M Net Gain in 2024, Driven by Loan-to-Equity Conversion - Barchart.com
Scinai Immunotherapeutics (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders - Barchart.com
Military Breakthrough: BrainChip and Raytheon Land $1.8M Air Force Deal for Next-Gen Radar - Stock Titan
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell - The Globe and Mail
Bayerische Motoren Werke ADR (OP: BMWYY - FinancialContent
Scinai regains Nasdaq compliance, eyes EIB loan conversion - Investing.com
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023 - Barchart.com
Scinai Immunotherapeutics Ltd Adr (SCNI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):